Evidence map›Paper›PMID 37347261›Full record

ArticleJournal of cancer research and clinical oncology2023

Identification a unique disulfidptosis classification regarding prognosis and immune landscapes in thyroid carcinoma and providing therapeutic strategies.

Zhanrong Feng, Qian Zhao, Ying Ding, Yue Xu, Xiaoxiao Sun, Qiang Chen, Yang Zhang, Juan Miao, Jingjing Zhu

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 26 citations in OpenAlex.

  1. The emerging roles of disulfidptosis in cancer.Apoptosis : an international journal on programmed cell death · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Zhanrong Feng *Department of Endocrinology, Shuyang County Hospital of Traditional Chinese Medicine, Suqian, 223600, Jiangsu, China. m17805288916@163.com.
Qian Zhao *Department of Endocrinology, Shuyang County Hospital of Traditional Chinese Medicine, Suqian, 223600, Jiangsu, China.
Ying DingDepartment of Endocrinology, Shuyang County Hospital of Traditional Chinese Medicine, Suqian, 223600, Jiangsu, China.
Yue XuDepartment of Endocrinology, Shuyang County Hospital of Traditional Chinese Medicine, Suqian, 223600, Jiangsu, China.
Xiaoxiao SunDepartment of Endocrinology, Shuyang County Hospital of Traditional Chinese Medicine, Suqian, 223600, Jiangsu, China.
Qiang ChenDepartment of Endocrinology, Shuyang County Hospital of Traditional Chinese Medicine, Suqian, 223600, Jiangsu, China.
Yang ZhangDepartment of Endocrinology, Shuyang County Hospital of Traditional Chinese Medicine, Suqian, 223600, Jiangsu, China.
Juan MiaoDepartment of Endocrinology, Shuyang County Hospital of Traditional Chinese Medicine, Suqian, 223600, Jiangsu, China.
Jingjing ZhuDepartment of Endocrinology, Shuyang County Hospital of Traditional Chinese Medicine, Suqian, 223600, Jiangsu, China. 471611718@qq.com.
Anyang Hospital of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThyroid carcinoma (THCA) is a common type of cancer worldwide, and its incidence has been increasing in recent years. Disulfidptosis, a recently defined form of metabolic-related regulated cell death (RCD), has been shown to play a sophisticated role in antitumor immunity. However, its mechanisms and functions are still poorly understood and the association between disulfidptosis and the prognosis of patients with papillary thyroid carcinoma remains to be elucidated. This study aims to investigate the connection between disulfidptosis and the prognosis of thyroid cancer, while also developing a prognostic index based on disulfidptosis genes. MATERIALS AND

methodsWe utilized 24 genes associated with disulfidptosis to create the classification and model. To gather data, we sourced gene expression profiles, somatic mutation information, copy number variation data, and corresponding clinical data from the TCGA database for patients with thyroid cancer. Additionally, we obtained single-cell transcriptome data GSE184362 from the Gene Expression Omnibus (GEO) database for further analysis.

resultsIn this study, we utilized 24 genes associated with disulfidptosis to identify two distinct groups with different biological processes using non-negative matrix factorization (NMF). Our findings showed that Cluster 1 is associated with chemokines, interleukins, interferons, checkpoint genes, and other important components of the immune microenvironment. Moreover, cluster 1 patients with high IPS scores may be more sensitive to immunotherapy. We also provide drug therapeutic strategies for each cluster patients based on the IC50 of each drug. The Enet model was chosen as the optimal model with the highest C-index and showed that patients with high risk had a worse prognosis and weak cell-to-cell interactions in THCA. Finally, we established a nomogram model based on multivariable cox and logistic regression analyses to predict the overall survival of THCA patients.

conclusionThis research provides new insight into the impact of disulfidptosis on THCA. Through a thorough examination of disulfidptosis, a new classification system has been developed that can effectively predict the clinical prognosis and drug sensitivity of THCA patients.

Indexed as

DNA Copy Number VariationsThyroid NeoplasmsHumansImmunotherapyPrognosisThyroid Cancer, PapillaryTumor MicroenvironmentClassificationDisulfidoptosisDrug sensitivityMachine learning modelNomogramThyroid carcinoma

Identifiers

PMID37347261
PMCPMC11796729
OpenAlexW4381597606

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.